Inari Medical, Inc. - Common Stock (NARI)

As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster

Discover 3 must-own investments for lifelong growth. From dividend stocks to a market-beating ETF, these picks offer stability, returns, and long-term wealth.

These mid-cap stocks had impressive gains last week, including Inari Medical, Unifirst Corporation, and Walgreens. Are they in your portfolio?

Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a growing global reach.

Inari is best-known for its series of catheter-like devices that remove blood clots.

On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.

The FDA labels Inari Medical's ClotTriever catheter recall as the most serious, citing risks like device entrapment and pulmonary emboli, linked to injuries and deaths.

With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.

NARI stock results show that Inari Medical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

NARI stock results show that Inari Medical missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.